Archrock (AROC)
(Delayed Data from NYSE)
$20.12 USD
+0.61 (3.13%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $20.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.12 USD
+0.61 (3.13%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $20.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum B VGM
Zacks News
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
by Zacks Equity Research
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
Get Rid of 5 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Overblown toxic stocks are generally susceptible to outside shocks and are loaded with a huge amount of debt.
Zacks.com featured highlights include: Altice USA, Archrock, Live Nation and First Majestic
by Zacks Equity Research
Zacks.com featured highlights include: Altice USA, Archrock, Live Nation and First Majestic
Cast These 4 Toxic Stocks Aside or Sell Short for Profit
by Zacks Equity Research
Overpriced toxic stocks are usually vulnerable to external shocks and burdened with a huge amount of debt.
Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock
by Zacks Equity Research
Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock
Discard These 4 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Overblown toxic stocks are usually susceptible to outside shocks and loaded with a huge amount of debt.
Archrock (AROC) Agrees to Buy Archrock Partners, Stock Falls
by Zacks Equity Research
Archrock (AROC) slips nearly 5% following the acquisition news.
Why Archrock (AROC) Could Be Positioned for a Slump
by Zacks Equity Research
Archrock (AROC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Why Archrock (AROC) Could Be Positioned for a Slump
by Zacks Equity Research
Archrock, Inc. (AROC) has witnessed a significant price decline in the past four weeks and it has seen negative earnings estimate revisions for the current quarter and the current year.
Bear of the Day: Halliburton (HAL)
by David Bartosiak
Roughed up stock in an even rougher sector
Your Next Stock Should Be Making New Highs
by Kevin Matras
This week, Kevin Matras talks about stocks making new highs and why you shouldn't be afraid to buy them. Highlighted stocks include MGA, IM, PLXS, EXH and RAD.